Worldwide Research, Development and Medical, Pfizer Inc, United States.
Worldwide Research, Development and Medical, Pfizer Inc, United States.
Drug Discov Today. 2022 Mar;27(3):697-704. doi: 10.1016/j.drudis.2021.12.010. Epub 2021 Dec 15.
Over the past decade, Pfizer has focused efforts to improve its research and development (R&D) productivity. By the end of 2020, Pfizer had achieved an industry-leading clinical success rate of 21%, a tenfold increase from 2% in 2010 and well above the industry benchmark of ∼11%. The company had also maintained the quality of innovation, because 75% of its approvals between 2016 and 2020 had at least one expedited regulatory designation (e.g., Breakthrough Therapy). Pfizer's Signs of Clinical Activity (SOCA) paradigm enabled better decision-making and, along with other drivers (biology and modality), contributed to this productivity improvement. These laid a strong foundation for the rapid and effective development of the Coronavirus 2019 (COVID-19) vaccine with BioNTech, as well as the antiviral candidate Paxlovid™, under the company's 'lightspeed' paradigm.
在过去的十年中，辉瑞（Pfizer）一直致力于提高其研发（R&D）生产力。截至 2020 年底，辉瑞的临床成功率达到了 21%，这是 2010 年的 20 倍，远高于行业约 11%的基准。该公司还保持了创新的质量，因为其在 2016 年至 2020 年期间获得批准的产品中有 75%至少有一个加速监管指定（例如突破性疗法）。辉瑞的临床活动迹象（SOCA）范式使决策更加明智，与其他驱动因素（生物学和模式）一起，推动了这一生产力的提高。这为辉瑞与生物技术公司合作快速有效地开发 2019 年冠状病毒（COVID-19）疫苗以及公司的“光速”范式下的抗病毒候选药物 Paxlovid™奠定了坚实的基础。
